长风药业：建议实施H股全流通
CF PHARMTECHCF PHARMTECH(HK:02652) Zhi Tong Cai Jing·2025-11-25 10:17

Core Viewpoint - Changfeng Pharmaceutical (02652) announced the board's approval to convert 107 million non-listed domestic shares held by 20 shareholders into H-shares, representing approximately 26.1% of the total issued share capital as of the announcement date [1] Group 1 - The conversion of shares requires filing with the China Securities Regulatory Commission [1] - The total number of non-listed domestic shares to be converted into H-shares is 107 million [1]